ObsEva SA (OBSV) Has Broken Out To A New High On Study Results
ObsEva SA (OBSV) announced Monday morning that its Phase 2b trial of linzagolix, for the treatment of endometriosis-associated pain, met its primary and secondary endpoints.
Source: RTTNews